Cryoprobe biopsy for the diagnosis of acute hypoxemic respiratory failure of undetermined origin

Introduction

Acute hypoxemic respiratory failure (AHRF) is a condition that comprises a wide array of entities. The acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure. ¹ As a syndrome, it has different causes, pathophysiological mechanisms and histologic changes, ² and its diagnosis is based on clinical and radiologic findings. ³ Several entities may mimic ARDS, and reaching a definite diagnosis – and consequently providing an appropriate treatment – can sometimes be a major challenge. ² When diagnosis of the underlying cause is not clear after performing a minimally invasive evaluation with bronchoscopy with bronchoalveolar lavage (BAL), many physicians opt for empirical treatments such as broad-spectrum antibiotics, diuretics, or immunosuppressive agents. Such strategies might sometimes be ineffective or even potentially injurious. In patients who do not improve after initial therapy, or those at risk of having serious complications with aggressive empirical treatments, having a histological sample might help reach a diagnosis and guide therapy.

Up to date, open lung biopsy (OLB) is the most common method for obtaining a pulmonary sample for most lung diseases. However, it is rarely performed in patients with AHRF because of potential severe complications. ⁴ A recent meta-analysis of 14 case series including 512 mechanically ventilated patients who underwent OLB showed that therapeutic changes occurred in 78% of the patients. However, 29% of them presented procedure-related complications and overall mortality after the procedure was 54%. ⁵ Transbronchial lung (TBLB) biopsy on the other hand, although a less invasive procedure, has a low diagnostic yield and high incidence of complications in ARDS ⁶ even when taking multiple samples. ⁷ Transbronchial lung cryobiopsy is a procedure that has proven to have a high diagnostic yield in diffuse lung diseases, quite similar to OLB in some series, with an acceptable safety profile and lower morbidity and mortality than surgical procedures. ⁸ Moreover, it provides larger samples than TBLB and more preserved tissue architecture for histologic interpretation.^9,10

Our purpose is to report our experience on cryoprobe lung biopsy in mechanically ventilated patients with hypoxemic respiratory failure and pulmonary infiltrates of unclear etiology.

Methods

Results

From January 2016 to March 2018, 90 patients were admitted to the ICU for AHRF. Among them, 10 patients (11.1%) underwent bronchoscopic cryobiopsy. The basal characteristics of the population are given in Table 1. Four (40%) patients met the Berlin criteria for ARDS and 1 (10%) patient was defined as an ARDS mimicker. Eight patients had a BAL performed prior to the cryobiopsy, and in the remaining two cases, the BAL was done at the same time. Only one BAL had a positive culture for Pseudomonas aeruginosa. All patients had a previous CT scan. The following CT patterns were seen: diffuse ground-glass opacities (N = 10), consolidation (N = 8), pleural effusion (N = 7), septal thickening (N = 1), crazy paving (N = 1), multiple nodules (N = 1), and mediastinal adenopathy (N = 4). It was the first lung biopsy for nine of the patients. The only patient who had a repeat biopsy had previously undergone a lung transplant. The average number of biopsies was four, and the mean duration of the procedure was 37 min.

OPEN IN VIEWER

Table 1.

Patients characteristics.

Characteristics	All patients (N = 10)
Age, years – median (IQR)	58 (34–78)
Female sex – no. (%)	6 (60%)
Previous lung disease – no. (%)
COPD	1 (10%)
Interstitial lung disease	1 (10%)
Lung transplant	1 (10%)
Comorbidities – no. (%)
Hypertension	4 (40%)
Diabetes	2 (20%)
Cancer	1 (10%)
Immunocompromised – no. (%)	6 (60%)
APACHE II score – median (IQR)	20 (13–22)
PaO2/FiO2 ratio – median (IQR)	203 (181–240)
Days from admission to biopsy – median (IQR)	3 (1–4)
Bilateral infiltrate on CT scan – no. (%)	10 (100%)
ARDS a – no. (%)	4 (40%)
Contributive biopsy – no. (%)	8 (80%)

All biopsies yielded a pathological diagnosis. Results are summarized in Table 2. Diffuse alveolar damage (DAD) was observed in four (40%) samples, one of them being organizing DAD (Figure 1). Other diagnoses were: histological findings compatible with drug toxicity (amiodarone and bleomycin) (N = 2 (20%)), tuberculosis (N = 1 (10%)), eosinophilic pneumonia (N = 1 (10%)), acute fibrinous organizing pneumonia (AFOP) (N = 1 (10%)), and bacterial pneumonia (N = 1 (10%)). One patient had a combination of DAD and cancer. Of the four patients who met ARDS criteria, three had DAD (75%) and one patient with DAD did not meet Berlin criteria (did not meet the timeframe criteria). Five of six patients (83.3%) who did not meet ARDS criteria had a pathological finding different to DAD. OPEN IN VIEWER

OPEN IN VIEWER

Table 2.

Histological findings.

Result of biopsy	n (%)
Diffuse alveolar damage	4 (40%)
Acute eosinophilic pneumonia	1 (10%)
Findings compatible with drug toxicity a	2 (20%)
Cancer	1 (10%)
AFOP	1 (10%)
Infectious disease
Tuberculosis	1 (10%)
Pseudomonas pneumonia	1 (10%)

a

Amiodarone and bleomycin toxicity.

Cryobiopsy was found to be contributive in 8 of the 10 patients (80%). High-dose steroids were started or continued in three cases and discontinued in two cases. Immunosuppression was discontinued in one case. Antimicrobials were changed to treat specific microorganisms in one case and discontinued in two cases. Amiodarone was discontinued in one of the patients with findings compatible with drug toxicity (bleomycin had already been discontinued in the other drug toxicity patient). When analyzing the subgroup of patients who did not meet Berlin criteria for ARDS, biopsy was found to be contributive in all of them.

Seven patients had type 1 bleeding (70%) and one patient had type 2 bleeding (10%). No patients presented hemodynamic instability related to a bleeding event. Three patients developed transient hypoxemia after the procedure which resolved within the following 60 min without the need for medical interventions. No patients developed pneumothorax or persistent air leak after the procedure. No biopsy-related death was recorded.

Discussion

In our small case series of highly selected patients with AHRF of unclear origin, we found a high diagnostic yield and contribution to guide management with cryoprobe biopsy. No major complications were associated with the procedure.

DAD was seen in 40% of the samples, in keeping with the findings of Philipponnet et al. ¹¹ Most of the patients (75%) with DAD met the Berlin criteria. In their cohort, Thille et al. ¹² found DAD in 45% of the autopsies of patients with ARDS. This difference might be explained by the fact that our sample is small. Moreover, although DAD is considered the pathological hallmark of ARDS, ¹³ both cannot be considered the same entity. ¹⁴ Interestingly, in the subgroup of patients who did not have ARDS according to the Berlin definition, biopsy showed a diagnosis different to DAD in 83% of the patients and led to a change in therapy in all the subjects in this group. This suggests that in the subgroup of patients where Berlin criteria is not met, it is more probable to obtain a different diagnosis than DAD. OLB has shown to be contributive in 60–80% in previous studies.^4,11,15–19 Our findings are therefore consistent with these results. It has to be noted that in many studies, the therapeutic changes reported included the decision to initiate steroids if the diagnosis was organizing DAD. This is not a common practice in our center as there is no robust evidence to support this treatment.^20–22

We observed no major complications associated with the procedure. Bleeding was the most common complication, and it resolved on its own in most of the patients. Only one patient required topical administration of epinephrine. OLB, as previously described, carries a higher risk of complications.^15,23,24 The mean number of biopsies was four, and this is both usual practice in our center and the recommended number of specimens suggested in the literature. ²⁵

This study has limitations. First, it is a retrospective study in a single center with a small sample size. Moreover, the procedure has to be performed by a trained interventional bronchoscopist. This makes generalization of our findings difficult. Second, this is a highly selected population of patients with AHRF, so we cannot exclude the possibility that both the diagnostic yield and the changes in therapy might be overestimated due to selection bias. However, both the indication for biopsy and the changes in therapy were documented in the medical charts. Third, although based on previously published criteria,^2,15 the definition of contributive biopsy might be considered arbitrary and broad. Nevertheless, we still found a significative contribution of cryobiopsy, even when steroids were not initiated for the treatment of organizing DAD.

To the best of our knowledge, this is the largest case series of cryoprobe biopsy in patients with hypoxemic respiratory failure of unclear origin. Ours is the first report of cryobiopsy findings in a population of hypoxemic respiratory failure with and without ARDS.

Our report of case-series shows that cryobiopsy is a safe procedure with a high diagnostic yield and can lead to changes in management in a highly selected group of patients in which diagnosis is not clear despite an adequate and extensive diagnostic process. Larger studies are needed to prove our findings and better identify those patients who are likely to benefit from this intervention.